Mirela Anghelina
Overview
Explore the profile of Mirela Anghelina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
690
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, et al.
Leukemia
. 2024 Jun;
38(7):1642-1644.
PMID: 38851853
No abstract available.
2.
Annunzio K, Ozga M, Huang Y, Anghelina M, Bhat S, Blachly J, et al.
EJHaem
. 2023 Nov;
4(4):1200-1202.
PMID: 38024604
No abstract available.
3.
Faraone J, Qu P, Evans J, Zheng Y, Carlin C, Anghelina M, et al.
Cell Rep Med
. 2023 May;
4(5):101049.
PMID: 37148877
New Omicron subvariants continue to emerge throughout the world. In particular, the XBB subvariant, which is a recombinant virus between BA.2.10.1.1 and BA.2.75.3.1.1.1, as well as the BA.2.3.20 and BR.2...
4.
Qu P, Faraone J, Evans J, Zheng Y, Carlin C, Anghelina M, et al.
Cell Rep
. 2023 Apr;
42(5):112443.
PMID: 37104089
Omicron subvariants continuingly challenge current vaccination strategies. Here, we demonstrate nearly complete escape of the XBB.1.5, CH.1.1, and CA.3.1 variants from neutralizing antibodies stimulated by three doses of mRNA vaccine...
5.
Epperla N, Zhao Q, Anghelina M, Neal J, Blachly J, Rogers K, et al.
Am J Hematol
. 2023 Feb;
98(5):E116-E118.
PMID: 36808760
No abstract available.
6.
Qu P, Faraone J, Evans J, Zheng Y, Carlin C, Anghelina M, et al.
bioRxiv
. 2023 Jan;
PMID: 36711991
Newly emerging Omicron subvariants continue to emerge around the world, presenting potential challenges to current vaccination strategies. This study investigates the extent of neutralizing antibody escape by new subvariants XBB.1.5,...
7.
Qu P, Evans J, Faraone J, Zheng Y, Carlin C, Anghelina M, et al.
Cell Host Microbe
. 2022 Dec;
31(1):9-17.e3.
PMID: 36476380
The continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron subvariants, including BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Here, we examine the neutralization resistance of these...
8.
Qu P, Evans J, Faraone J, Zheng Y, Carlin C, Anghelina M, et al.
bioRxiv
. 2022 Oct;
PMID: 36299423
Continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron subvariants, including BQ.1, BQ. 1.1, BA.4.6, BF.7 and BA.2.75.2. Here we examine the neutralization resistance of these...
9.
Andritsos L, Anghelina M, Neal J, Blachly J, Mathur P, Lele O, et al.
Leuk Lymphoma
. 2022 Sep;
63(13):3021-3031.
PMID: 36070610
Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder, comprising only 2% of all leukemias. The Hairy Cell Leukemia Foundation (HCLF) has developed a patient data registry to enable investigators...
10.
Anghelina M, Naughton M, Zhao Q, Ruppert A, Neal J, Rogers K, et al.
Leuk Res
. 2022 Sep;
121:106943.
PMID: 36064473
No abstract available.